Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events

被引：0
|
作者：
Gazzah, Anas
Tabernero, Josep
Italiano, Antoine
Cousin, Sophie
Barlesi, Fabrice
Lena, Herve
Bedard, Philippe L.
Ryu, Min-Hee
Sung, Kyung Rim
Cho, Byoung Chul
Calvo, Emiliano
Yoruk, Semra
Chadjaa, Mustapha
Masson, Nina
Fagniez, Nathalie
Balaguer, Oscar
Brosa, Helena
Gabison, Eric E.
机构：
[1] Gustave Roussy, Drug Dev Dept, Villejuif, France
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[5] Inst Bergonie, Dept ofMedicine, Bordeaux, France
[6] Aix Marseille Univ, INSERM, CNRS, CRCM,APHM,CEPCM,CLIP2, Marseille, France
[7] Gustave Roussy, Dept Med Oncol, Villejuif, France
[8] CHU Rennes, Rennes, France
[9] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[10] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[11] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea
[12] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[13] Ctr Integral Oncol Clara Campal, START Madrid CIOCC, Madrid, Spain
[14] Sanofi Inc, R&D Oncol Dev, Istanbul, Turkiye
[15] Sanofi, Clin Dev, Vitry Sur Seine, France
[16] Sanofi, IT&M STATS, Neuilly Sur Seine, France
[17] Sanofi, Pharmacokinet Dynam & Metab, Chilly Mazarin, France
[18] Vall dHebron Hosp, Dept Ophthalmol, Barcelona, Spain
[19] Hop Fdn Rothschild, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15003
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors
    Yamazaki, Kentaro
    Yoshino, Takayuki
    Honda, Kazunori
    Kuboki, Yasutoshi
    Kawakami, Takeshi
    Mitani, Seiichiro
    Nakamura, Yoshiaki
    Taniguchi, Hiroya
    Bando, Hideaki
    Tanaka, Tomoyuki
    Tada, Keisuke
    Fagniez, Nathalie
    Muro, Kei
    ANNALS OF ONCOLOGY, 2022, 33 : S506 - S506
  • [2] Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
    Tabernero, Josep
    Bedard, Philippe L.
    Bang, Yung-Jue
    Vieito, Maria
    Ryu, Min-Hee
    Fagniez, Nathalie
    Chadjaa, Mustapha
    Soufflet, Christine
    Masson, Nina
    Gazzah, Anas
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1662 - 1671
  • [3] Safety profile of avelumab in patients with advanced solid tumors: A JAVELIN pooled analysis of phase 1 and 2 data.
    Kelly, Karen
    Infante, Jeffrey R.
    Taylor, Matthew H.
    Patel, Manish R.
    Gordon, Michael S.
    Wong, Deborah Jean Lee
    Iannotti, Nicholas
    Mehnert, Janice M.
    Loos, Anja
    Koch, Helga
    Speit, Isabel
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors
    Tabernero, J.
    Bedard, P.
    Bang, Y-J.
    Vieito, M.
    Ryu, M-H.
    Fagniez, N.
    Yoruk, S.
    Charbonnier, L.
    Soufflet, C.
    Masson, N.
    Gazzah, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S589 - S590
  • [5] Safety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data
    Decaens, T.
    Ryoo, B. -Y.
    Falchook, G. S.
    Veillon, R.
    Doi, T.
    Yamazaki, K.
    Hong, D.
    Qin, S.
    Scheele, J.
    Bruns, R.
    Berghoff, K.
    Faivre, S.
    Paik, P. P.
    ANNALS OF ONCOLOGY, 2019, 30 : 181 - +
  • [6] Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)
    Gazzah, Anas
    Lee, Joon Sang
    Wang, Emma
    Ternes, Nils
    Wang, Hong
    Boitier, Eric
    lartigau, AuDe
    Chadjaa, Mustapha
    Dib, Colette
    Muzard, Gaelle
    Valence, Sandrine
    Remaury, Anne
    Palu, Cintia C.
    Bauchet, Anne-Laure
    CANCER RESEARCH, 2023, 83 (08)
  • [7] Safety Profile of Avelumab in Patients With Advanced Solid Tumors: A Pooled Analysis of Data From the Phase 1 JAVELIN Solid Tumor and Phase 2 JAVELIN Merkel 200 Clinical Trials
    Kelly, Karen
    Infante, Jeffrey R.
    Taylor, Matthew H.
    Patel, Manish R.
    Wong, Deborah J.
    Iannotti, Nicholas
    Mehnert, Janice M.
    Loos, Anja H.
    Koch, Helga
    Speit, Isabell
    Gulley, James L.
    CANCER, 2018, 124 (09) : 2010 - 2017
  • [8] Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors
    Cioffi, A.
    LeCesne, A.
    Blay, J.
    Delaloge, S.
    Yovine, A.
    Maki, R.
    Nieto, A.
    Jiao, J. J.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Yoshida, Kenichiro
    Seraj, Jabed
    Weaver, Racquel
    Lemech, Charlotte
    Todaro, Thomas G.
    Pant, Shubham
    Arkenau, Hendrik-Tobias
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1275 - 1283
  • [10] Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
    Johanna C. Bendell
    Manish R. Patel
    Kenichiro Yoshida
    Jabed Seraj
    Racquel Weaver
    Charlotte Lemech
    Thomas G. Todaro
    Shubham Pant
    Hendrik-Tobias Arkenau
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1275 - 1283
12345